Dr. Vaena reported that phase III evidence for niraparib significantly extends radiographic PFS and enhances quality of life in castration‑sensitive prostate cancer—especially for BRCA‑mutated patients—while he stressed the imperative of germline/somatic testing, optimal timing of PARP‑inhibitor use, and PSMA‑PET guidance to individualize therapy amid ongoing trials.